Dividends & Buybacks ·
Nuwellis, Inc. has approved a one-for-thirty-five reverse stock split of its issued and outstanding common stock
NUWENuwellis, Inc.
Nuwellis, Inc. has approved a one-for-thirty-five reverse stock split of its issued and outstanding common stock. Following Board approval on June 16, 2026, the company filed a Certificate of Amendment in Delaware on June 23, 2026. The split becomes effective at 5:00 p.m. ET on June 25, 2026, with shares expected to trade on a split-adjusted basis starting June 26, 2026. Every 35 existing shares will convert into one share of common stock, and proportionate adjustments will apply to preferred stock, options, and warrants. Fractional shares will be settled in cash based on the closing price from the last trading day before the effective date. Nuwellis, Inc. is a medical device company.